Scarica l'app Stockscreener
64.36
1.41%
1.015
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$63.35
Aprire:
$63.41
Volume 24 ore:
120.04K
Relative Volume:
0.31
Capitalizzazione di mercato:
$1.36B
Reddito:
$486.82M
Utile/perdita netta:
$18.78M
Rapporto P/E:
78.49
EPS:
0.82
Flusso di cassa netto:
$100.45M
1 W Prestazione:
+2.33%
1M Prestazione:
+7.09%
6M Prestazione:
+19.24%
1 anno Prestazione:
+5.77%
Intervallo 1D:
$62.81
$64.50
Intervallo di 1 settimana:
$61.17
$65.19
Portata 52W:
$52.50
$77.00
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Nome
Ani Pharmaceuticals Inc
Settore
Telefono
(218) 634-3500
Indirizzo
210 MAIN STREET WEST, BAUDETTE, MN
Confronta ANIP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
64.25 | 1.36B | 486.82M | 18.78M | 100.45M | 0.82 |
|
RGC
Regencell Bioscience Holdings Ltd
|
62.89 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
156.57 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.47 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.97 | 47.60B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.05 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-14 | Iniziato | Jefferies | Buy |
| 2025-03-12 | Iniziato | JP Morgan | Overweight |
| 2024-12-11 | Iniziato | Leerink Partners | Outperform |
| 2024-10-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-15 | Iniziato | CapitalOne | Overweight |
| 2023-08-22 | Reiterato | H.C. Wainwright | Buy |
| 2023-03-01 | Iniziato | Guggenheim | Buy |
| 2022-09-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-02 | Iniziato | Truist | Buy |
| 2020-05-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-05-10 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Reiterato | Canaccord Genuity | Buy |
| 2017-07-31 | Iniziato | Canaccord Genuity | Buy |
| 2017-02-22 | Downgrade | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Iniziato | Raymond James | Strong Buy |
| 2016-05-24 | Downgrade | Standpoint Research | Buy → Hold |
| 2015-11-13 | Iniziato | Standpoint Research | Buy |
| 2015-09-28 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Reiterato | Oppenheimer | Outperform |
| 2015-08-04 | Reiterato | ROTH Capital | Neutral |
| 2015-07-31 | Reiterato | Oppenheimer | Outperform |
| 2015-07-15 | Reiterato | ROTH Capital | Neutral |
| 2015-06-23 | Reiterato | Oppenheimer | Outperform |
| 2015-05-18 | Reiterato | ROTH Capital | Neutral |
| 2015-05-06 | Reiterato | Oppenheimer | Outperform |
| 2015-04-10 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Reiterato | ROTH Capital | Buy |
| 2015-02-18 | Reiterato | Oppenheimer | Outperform |
Mostra tutto
Ani Pharmaceuticals Inc Borsa (ANIP) Ultime notizie
ANI Pharmaceuticals (ANIP) Reveals New Preclinical Findings on Cortrophin Gel | ANIP Stock News - GuruFocus
ANI Pharmaceuticals Announces Presentation of New Preclinical Data - GlobeNewswire
Breakthrough Arthritis Treatment Data: Cortrophin Gel Successfully Reduces Joint Inflammation in Preclinical Study - Stock Titan
GAMMA Investing LLC Purchases 94,464 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 13,948 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
ANI Pharmaceuticals at Jefferies Conference: Strategic Growth in Rare Diseases - Investing.com Canada
ANI Pharmaceuticals To Present At Jefferies Global Conference; Webcast At 2:35 PM ET - Nasdaq
ANI Pharmaceuticals Inc (ANIP) Shares Up 3.19% on Jun 2 - GuruFocus
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Nuveen Asset Management LLC - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
BNP Paribas Financial Markets Reduces Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewswire
Bank of America Corp DE Raises Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals CEO Nikhil Lalwani to Share Strategic Updates at Jefferies Healthcare Conference - Stock Titan
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Buy” from Analysts - Defense World
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead - Yahoo Finance
ANI Pharmaceuticals Expands Stock Plans and Shares By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals initiates Phase IV trial of gel for acute gout flares - MSN
ANI Pharmaceuticals Expands Stock Plans and Shares - Investing.com Australia
ANI Pharmaceuticals Approves Key Proposals at Annual Meeting - TipRanks
Have Insiders Sold ANI Pharmaceuticals Shares Recently? - simplywall.st
ANI Pharmaceuticals Launches Phase 4 Trial of Cortrophin Gel for Acute Gout Flares - marketscreener.com
ANI Pharmaceuticals (ANIP) Starts Phase 4 Trial for Acute Gout Treatment | ANIP Stock News - GuruFocus
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares - The Manila Times
ANI Pharmaceuticals Announces Initiation of Phase 4 - GlobeNewswire
ANI Raises Generics Guidance As Exclusive Prucalopride Drives Growth - insights.citeline.com
ANI Pharmaceuticals at H.C. Wainwright: Rare Disease Growth Focus By Investing.com - Investing.com India
ANI Pharmaceuticals To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq
Ameriprise Financial Inc. Raises Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
The Manufacturers Life Insurance Company Sells 291 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation - simplywall.st
Price T Rowe Associates Inc. MD Has $403,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Voyager Therapeutics (VYGR) and Privia Health Group (PRVA) - The Globe and Mail
Stifel Financial Corp Acquires 1,425 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals (ANIP) Price Target Raised by Raymond James - GuruFocus
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ - GlobeNewswire
ANI Pharmaceuticals (ANIP) Receives Buy Rating from Guggenheim | - GuruFocus
ANI Pharmaceuticals (ANIP) Receives Buy Rating from Guggenheim | ANIP Stock News - GuruFocus
ANI Pharmaceuticals raises 2025 revenue guidance to $768M-$793M with 25%-29% growth - MSN
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ANI Pharmaceuticals beats Q1 2025 forecasts, stock surges - Investing.com UK
ANI Pharmaceuticals Inc (ANIP) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insigh - GuruFocus
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insight - GuruFocus
ANI Pharmaceuticals Reports Record Q1 2025 Results - TipRanks
Earnings call transcript: ANI Pharmaceuticals beats Q1 2025 forecasts, stock surges By Investing.com - Investing.com South Africa
Ani Pharmaceuticals Inc Azioni (ANIP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):